FEATURED

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

  • All
  • Education
  • Events
  • Press Releases
See more news
See more press releases

Social media

nspharmainc NS Pharma @nspharmainc ·
14 Jan

We’re excited to join families, caregivers, clinicians and researchers for a day of learning and connection at the latest #CureDuchenne Workshop!

📅 Jan 17, 8 AM–4 PM
📍 Miami Marriott Dadeland.

Register here: https://ow.ly/5Wr950XWByg

#RareDisease #NSPharma https://x.com/NSPharmaInc/status/2011453701387411636/photo/1

nspharmainc NS Pharma @nspharmainc ·
12 Jan

We’re continuing to grow our team at #NSPharma. We’re #NowHiring a Senior Director, Market Access, a key role for an experienced leader passionate about improving access to therapies for people living with #RareDiseases.

Learn more and apply: https://ow.ly/E25F50XVpZ6 https://x.com/NSPharmaInc/status/2010728774531256724/photo/1

nspharmainc NS Pharma @nspharmainc ·
8 Jan

We’re excited to connect with everyone in Memphis for the #CureDuchenne Community Dinner!

Join families and caregivers for an evening of shared experiences and support.

📅 Jan 10, 6–9 PM
📍 Fleming’s Prime Steakhouse

Reserve your spot: https://ow.ly/iwJi50XTmkO

#NSPharma https://x.com/NSPharmaInc/status/2009279349355061717/photo/1

nspharmainc NS Pharma @nspharmainc ·
6 Jan

The dystrophin gene has 79 exons.

#ExonSkipping works by skipping a specific exon to help the body compensate for some mutations

A simple genetic test can show which exons are affected and whether exon-skipping may be an option.

Learn more: https://ow.ly/gOMe50XJwKc

#Duchenne https://x.com/NSPharmaInc/status/2008554252696691056/photo/1

nspharmainc NS Pharma @nspharmainc ·
22 Dec

As the year ends, we extend our heartfelt thanks to our colleagues, friends and families across the rare disease community.

Your collaboration inspires our work and drives progress. From all of us at #NSPharma, we wish you a happy holiday season 💙

#RareDiseases https://x.com/NSPharmaInc/status/2003118590736666656/photo/1

nspharmainc NS Pharma @nspharmainc ·
19 Dec

Please welcome Kunal Kaushal to #NSPharma as Director of Data, Analytics and Reporting!

With 17+ years in commercial analytics, market access and patient journey design in oncology, cardiology, and rare diseases, he brings deep expertise from Novartis and Accenture.

#NewHire https://x.com/NSPharmaInc/status/2002031398681469122/photo/1

nspharmainc NS Pharma @nspharmainc ·
17 Dec

#EGPA is a rare condition that can involve asthma, sinusitis, skin rashes and nerve pain, making diagnosis difficult. #NSPharma is working to change that with NS-229, now in phase 2 trials and offering new hope for patients.

Learn more: https://ow.ly/hQNf50XJwaj

#RareDiseases https://x.com/NSPharmaInc/status/2001306684833046816/photo/1